Lineage Cell Therapeutics, Inc.

$1.54
+0.03 (+1.99%)

Volume:

965.285K ($1.49M)

Market Capitalization:

$383.59M

Lineage Cell Therapeutics Price Chart

Lineage Cell Therapeutics Price Chart6:57 AM8:17 AM9:37 AM10:57 AM12:17 PM1:37 PM2:57 PM1.551.541.531.521.511.501.50

Lineage Cell Therapeutics Volume Chart

Lineage Cell Therapeutics Volume Chart6:57 AM8:17 AM9:37 AM10:57 AM12:17 PM1:37 PM2:57 PM146.70K125.74K104.78K83.83K62.87K41.91K20.96K

Lineage Cell Therapeutics Market Segments

Regular Trading Hours

+0.02(+1.32%)
Open$1.52
Close$1.54
Low$1.49
Low Change-0.03 (-1.97%)
High$1.55
High Change+0.03 (+1.97%)
Range$0.06
Volume965.285K
Dollar Volume$1.49M

Premarket

*No Trades in Segment

After Hours Yesterday

+0.02(+1.32%)
Open$1.51
Close$1.53
Low$1.48
Low Change-0.03 (-1.99%)
High$1.53
High Change+0.02 (+1.32%)
Range$0.05
Volume14.201K
Dollar Volume$21.73K

Regular Trading Hours Yesterday

+0.05(+3.42%)
Open$1.46
Close$1.51
Low$1.46
Low Change-0.00 (-0.10%)
High$1.52
High Change+0.06 (+4.11%)
Range$0.06
Volume1.773M
Dollar Volume$2.68M

Premarket Yesterday

+0.01(+0.68%)
Open$1.47
Close$1.48
Low$1.47
Low Change0.00 (0.00%)
High$1.50
High Change+0.03 (+2.04%)
Range$0.03
Volume4.978K
Dollar Volume$7.37K

Lineage Cell Therapeutics Moving Averages

5 Day Moving Average (SMA5)$1.53
10 Day Moving Average (SMA10)$1.59
20 Day Moving Average (SMA20)$1.57
50 Day Moving Average (SMA50)$1.64
100 Day Moving Average (SMA100)$1.66
200 Day Moving Average (SMA200)$1.56

Lineage Cell Therapeutics Statistics

Average Volume (30 Days)1.04M
P/E Ratio (Current)-6.00
EPS (Current)-$0.26
Dividend Yield0.00%
Free Cash Flow-$19.44M
Cash Ratio3.59
Current Ratio5.20
Quick Ratio5.20
Debt to Equity0.00
Enterprise Value$347.85M
EV to EBITDA-16.50
EV to Sales23.90
Price to Book8.72
Price to Cash Flow
Price to Free Cash Flow
Price to Sales26.70
Return on Assets-0.56%
Return on Equity-1.43%

Lineage Cell Therapeutics Stock Splits

There have been no stock splits for Lineage Cell Therapeutics (LCTX).

Lineage Cell Therapeutics Dividends

There have been no dividends for Lineage Cell Therapeutics (LCTX).